Overview

A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
An Open-Label, Multi-Center Study to Assess the Safety and Pharmacokinetics of BRCX014 Combined with Standard-of-Care Treatment in Subjects with Glioblastoma
Phase:
Phase 1
Details
Lead Sponsor:
Leaf Vertical Inc.
Treatments:
Dacarbazine
Temozolomide